# Phase 2 Study Evaluating the Safety and Efficacy of Microneedle-mediated Delivery of Doxorubicin (D-MNA) in Patients With Nodular Basal Cell Carcinoma.

> **NCT06608238** · PHASE2 · COMPLETED · sponsor: **SkinJect, Inc.** · enrollment: 90 (actual)

## Conditions studied

- Nodular Basal Cell Carcinoma

## Interventions

- **DRUG:** D-MNA 200µg
- **DRUG:** D-MNA 100µg
- **OTHER:** Microneedle Array Alone

## Key facts

- **NCT ID:** NCT06608238
- **Lead sponsor:** SkinJect, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-09-03
- **Primary completion:** 2026-03-05
- **Final completion:** 2026-03-13
- **Target enrollment:** 90 (ACTUAL)
- **Last updated:** 2026-05-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06608238

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06608238, "Phase 2 Study Evaluating the Safety and Efficacy of Microneedle-mediated Delivery of Doxorubicin (D-MNA) in Patients With Nodular Basal Cell Carcinoma.". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06608238. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*